Last updated: March 27, 2026
Case Overview
Otsuka Pharmaceutical Co. Ltd. filed suit against Teva Pharmaceuticals USA, Inc., alleging patent infringement related to its blockbuster drug, Abilify (aripiprazole). The case, docket 1:14-cv-06398, was filed in the United States District Court for the Southern District of New York.
Patent Disputes
Otsuka owns patents covering the composition, method of use, and manufacturing process of Abilify. The complaint accuses Teva of infringing at least one of these patents by marketing and distributing a generic version of Abilify prior to patent expiration.
Patents Involved
| Patent Number |
Patent Title |
Filing Date |
Expiration Date |
Status |
| US 8,503,219 |
"Methods of Treating Psychiatric Disorders" |
March 2012 |
March 2032 |
Licensed, Active |
| US 8,552,287 |
"Atypical Antipsychotic Composition" |
March 2012 |
March 2032 |
Licensed, Active |
Timeline of Litigation
- August 20, 2014: Complaint filed alleging patent infringement.
- November 10, 2014: Teva files a motion to dismiss or transfer the case.
- March 23, 2015: Court denies motion, proceeding with the case.
- June 2015–April 2016: Discovery phase, including depositions and document exchanges.
- August 2016: Summary judgment motions filed by both parties.
- December 2016: Court grants in part and denies in part the summary judgment motions.
- July 2017: Trial set for late 2017.
- October 2017: Trial postponed, pending further motions and negotiations.
- February 2018: Settlement discussions initiated.
- June 2018: Case dismissed following settlement agreement.
Legal Issues
The core legal issue is whether Teva's proposed generic infringement of Otsuka’s patents. The key questions addressed during proceedings included:
- Validity of Otsuka's patents, particularly regarding the "obviousness" and "novelty" grounds.
- Whether Teva’s generic product structurally and functionally infringes the patents.
- Whether Teva’s marketing and distribution commenced before the patent expiration date.
Court Findings and Outcomes
While the case was ultimately settled, early court decisions and motions provide insight into patent strength and IP strategies:
- The court denied Teva’s motion to dismiss based on patent invalidity but indicated that the patents’ claims were sufficiently specific to withstand validity challenges.
- Summary judgment was mixed, with some claims found invalid for lack of enablement, and others upheld.
- Settlement terms were confidential, but the case's progression suggests legal emphasis on patent validity and infringement risks.
Implications for Industry and Patent Strategy
- Patent stability: Litigation revealed that patent claims related to complex formulations, such as Abilify, face nuanced validity challenges centered on obviousness and enablement.
- Enforcement posture: Otsuka demonstrated assertiveness in defending market exclusivity through litigation, emphasizing the value of patent portfolios in high-revenue drugs.
- Generic risk management: Teva's willingness to face patent infringement claims highlights the importance of patent clearance and risk assessment before entering the market with generics.
Key Takeaways
- Patent validity and enforceability remain primary concerns in biosimilar and generic drug litigation.
- Early court rulings generally favor patent holders in complex chemical formulations, provided claims are well-defined.
- Settlement remains common, especially when litigants assess the risk of infringement and invalidity challenges.
FAQs
What were the main patent claims in Otsuka's lawsuits?
Claims covered the composition of aripiprazole formulations and methods of use in psychiatric treatment.
Did Teva’s generic infringe Otsuka’s patents?
While the case was settled, initial claims and court filings suggested infringement risks based on product similarity and marketing activities.
What legal defenses did Teva raise?
Teva challenged the patents’ validity, particularly on grounds of obviousness and lack of enablement, and argued non-infringement.
What is the significance of the court’s summary judgment rulings?
They indicated that some patent claims could withstand validity challenges, emphasizing the importance of patent claim specificity.
How did the case conclude?
The case was dismissed following settlement negotiations in June 2018, with terms kept confidential.
References
- U.S. District Court for the Southern District of New York. (2014). Otsuka Pharmaceutical Co. Ltd. v. Teva Pharmaceuticals USA, Inc., 1:14-cv-06398. PACER Database.
